Page 103 - NobleCon20-Book-Project

Jaguar Health, Inc.

SELECTED FINANCIAL ITEMS JAGX

(in millions of USD)
CQ4 '23 CQ1 '24 CQ2 '24 CQ3 '24 LTM
Income Statement Key Items
Total Revenue 2.30 2.35 2.72 3.11 10.48
Gross Profit 1.61 1.92 2.29 2.57 8.40
Gross Margin 70% 82% 84% 83% 80%
EBIT (7.19) (8.22) (7.20) (7.26) (29.86)
EBIT Margin -312% -349% -264% -234% -285%
Net Income to Common Shareholders (9.31) (9.37) (9.63) (10.02) (38.33)
Net Margin -405% -398% -354% -322% -366%

Balance Sheet Key Items
Total Assets 50.76 55.39 61.46 58.47 58.47
Cash & Short Term Investments 6.47 11.67 16.05 13.27 13.27
% of Assets 13% 21% 26% 23% 23%
Current Assets -Total 27.96 33.71 40.11 36.64 36.64
% of Assets 55% 61% 65% 63% 63%
Total Liabilities 45.87 41.09 42.40 42.88 42.88
% of Assets 90% 74% 69% 73% 73%
Current Liabilities - Total 13.99 17.81 19.13 19.87 19.87
% of Assets 28% 32% 31% 34% 34%
Long Term Debt 30.99 21.72 21.81 21.66 21.66
% of Assets 61% 39% 35% 37% 37%
Total Equity 4.90 14.30 19.06 15.58 15.58
% of Assets 10% 26% 31% 27% 27%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (7.45) (7.05) (8.17) (6.34) (29.01)
Net Cash Flow - Investing NA NA (0.02) 0.00 (0.02)
Net Cash Flow - Financing 10.65 12.27 12.57 3.53 39.02

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twentieth Annual Small & Microcap Investor Conference